JP2020500864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500864A5 JP2020500864A5 JP2019528756A JP2019528756A JP2020500864A5 JP 2020500864 A5 JP2020500864 A5 JP 2020500864A5 JP 2019528756 A JP2019528756 A JP 2019528756A JP 2019528756 A JP2019528756 A JP 2019528756A JP 2020500864 A5 JP2020500864 A5 JP 2020500864A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- fixed dose
- testosterone
- discontinuation
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 29
- 229940124597 therapeutic agent Drugs 0.000 claims 29
- 210000002966 serum Anatomy 0.000 claims 21
- 229960003604 testosterone Drugs 0.000 claims 19
- MOFKIKISDIQWLD-NQPKZJONSA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] tridecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCCCC)[C@@]1(C)CC2 MOFKIKISDIQWLD-NQPKZJONSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 4
- 206010002261 Androgen deficiency Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000007902 hard capsule Substances 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 239000007901 soft capsule Substances 0.000 claims 2
- 238000009165 androgen replacement therapy Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002710 gonadal effect Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428167P | 2016-11-30 | 2016-11-30 | |
| US201662428317P | 2016-11-30 | 2016-11-30 | |
| US62/428,317 | 2016-11-30 | ||
| US62/428,167 | 2016-11-30 | ||
| PCT/US2017/064083 WO2018102618A1 (en) | 2016-11-30 | 2017-11-30 | Oral testosterone tridecanoate therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500864A JP2020500864A (ja) | 2020-01-16 |
| JP2020500864A5 true JP2020500864A5 (enExample) | 2021-11-11 |
Family
ID=62240656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528756A Pending JP2020500864A (ja) | 2016-11-30 | 2017-11-30 | 経口トリデカン酸テストステロン療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20180153905A1 (enExample) |
| EP (1) | EP3548037B1 (enExample) |
| JP (1) | JP2020500864A (enExample) |
| CA (1) | CA3078724A1 (enExample) |
| ES (1) | ES2983643T3 (enExample) |
| WO (1) | WO2018102618A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1871384A4 (en) | 2005-04-15 | 2012-01-25 | Clarus Therapeutics Inc | SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| WO2018102618A1 (en) | 2016-11-30 | 2018-06-07 | Lipocine Inc. | Oral testosterone tridecanoate therapy |
| EP3824296A4 (en) | 2018-07-20 | 2022-04-27 | Lipocine Inc. | LIVER DISEASE |
| US11931367B2 (en) | 2021-09-30 | 2024-03-19 | Lipocine Inc. | Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy |
| US12257257B2 (en) | 2023-07-27 | 2025-03-25 | Lipocine, Inc. | Testosterone dodecanoate compositions and methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130225544A1 (en) * | 2009-01-08 | 2013-08-29 | Lipocine Inc. | Lipobalanced long chain testosterone esters for oral delivery |
| US20140288039A1 (en) | 2009-01-08 | 2014-09-25 | Lipocine Inc. | Lipobalanced long chain testosterone prodrugs for oral delivery |
| TW201521731A (zh) * | 2013-03-15 | 2015-06-16 | 利波辛股份有限公司 | 用於口服之脂平衡的長鏈睪固酮酯 |
| WO2015100406A1 (en) | 2013-12-26 | 2015-07-02 | Clarus Therapeutics, Inc. | Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents |
| RU2017110076A (ru) | 2014-08-28 | 2018-09-28 | Липосин Инк. | Фармацевтическая композиция и способы |
| WO2018102618A1 (en) | 2016-11-30 | 2018-06-07 | Lipocine Inc. | Oral testosterone tridecanoate therapy |
-
2017
- 2017-11-30 WO PCT/US2017/064083 patent/WO2018102618A1/en not_active Ceased
- 2017-11-30 US US15/828,320 patent/US20180153905A1/en not_active Abandoned
- 2017-11-30 ES ES17876230T patent/ES2983643T3/es active Active
- 2017-11-30 EP EP17876230.8A patent/EP3548037B1/en active Active
- 2017-11-30 CA CA3078724A patent/CA3078724A1/en active Pending
- 2017-11-30 JP JP2019528756A patent/JP2020500864A/ja active Pending
-
2019
- 2019-12-26 US US16/727,737 patent/US10881670B2/en active Active - Reinstated
-
2020
- 2020-12-23 US US17/132,167 patent/US11672807B1/en active Active
-
2023
- 2023-05-02 US US18/310,784 patent/US11992496B1/en active Active
-
2024
- 2024-04-22 US US18/641,597 patent/US12161651B1/en active Active
- 2024-11-06 US US18/938,942 patent/US12303517B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503269A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| AU2010260585B2 (en) | Compositions and methods for treatment of Multiple Sclerosis | |
| JP2015512406A5 (enExample) | ||
| WO2013079964A1 (en) | Combination treatment of cancer | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2020097624A (ja) | モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 | |
| JP2017533972A5 (enExample) | ||
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| JP2012502047A5 (enExample) | ||
| AU2017279592A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| ES2965454T3 (es) | Protocolo mejorado para el tratamiento de la nefritis lúpica | |
| CN117355297A (zh) | 用于诱导褐色脂肪生成的方法和组合物 | |
| JP2020519576A5 (enExample) | ||
| JP2015522077A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP2019533672A5 (enExample) | ||
| Luqmani | Discontinuation of therapies in vasculitis | |
| TWI726355B (zh) | 苯甲酸或其鹽及衍生物用於預防或治療抗n-甲基-d-天冬胺酸受體腦炎之用途 | |
| Rafiei et al. | Comparing the effectiveness of albendazole and combination of albendazole and praziquantel in experimental hydatidosis |